CD274 and neoplasm: PD-L1 expression has emerged as a biomarker to predict response to ICIs as high levels of PD-L1 are often associated with better treatment outcomes7, while low levels of tumor infiltrating lymphocytes (TILs) are associated with lack of response or eventual resistance7,8.